By Maggie Fick and Kashish Tandon LONDON/BENGALURU (Reuters) -Drugmaker stocks gained a temporary reprieve on Thursday as U.S ...

Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A ...

DexCom Inc. closed 52.01% short of its 52-week high of $141.99, which the company achieved on April 9th.

Eligible residents living with diabetes in Saskatchewan who rely on any type of insulin may be eligible to receive coverage ...

The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...

The A1C test measures average blood sugar levels over the past two to three months, which can identify prediabetes or ...

DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic ...

Josh Adams and Taulupe Faletau are set to provide an injury boost for Cardiff before the Challenge Cup last-16 tie against ...

A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its ...

Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former ...

President Trump's new tariffs have led to a global market meltdown, impacting major U.S. tech companies like Apple and retail ...

Diabetes management has relied on finger-prick blood glucose testing and continuous glucose monitors (CGMs) for decades.